COMMUNIQUÉS West-GlobeNewswire

Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
14/05/2024
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to [...]
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
14/05/2024
LA JOLLA, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector
14/05/2024
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector Paris - France - May 14, 2024 - The Alliance [...]
L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote
14/05/2024
L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote Paris - France – 14 mai 2024 – L’Alliance [...]
Periodemeddelelse Første Kvartal 2024
14/05/2024
Selskabet har opnået følgende resultat for første kvartal 2024: EBIT: negativt DKK 0.9 mio. De strategiske partnerskaber har bidraget med en indtægt på DKK 0.6 mio. Egenkapital ultimo marts 2024: DKK 13.4 mio. Business [...]
Coloplast expands its Luja™ portfolio with next generation catheter for women
14/05/2024
The female intermittent catheter enables complete bladder emptying in one free flow 1 , aiming to reduce the risk of urinary tract infections 2 . Following the successful launch of Luja with Micro-hole Zone Technology, [...]
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R&D Committee
14/05/2024
Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that has resulted in the [...]
Aino Health AB (publ): interim report january-march 2024
14/05/2024
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. Extending existing contracts. Improved cash flow. January – March 2024 • Net sales [...]
Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024
14/05/2024
GUANGZHOU, China, May 14, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) [...]
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
14/05/2024
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular [...]
Aurora Spine Corporation Announces First Quarter 2024 Financial Results
14/05/2024
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a [...]
Pacific Health Care Organization, Inc. Reports its First Quarter 2024 Results
14/05/2024
Irvine, May 13, 2024 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the Securities and Exchange Commission (the “Commission”) its quarterly report on Form 10-Q [...]
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
14/05/2024
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 [...]
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
14/05/2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III [...]
Cannabix Technologies Enters into Marketing Agreements
14/05/2024
VANCOUVER, British Columbia, May 13, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (the “Company or Cannabix”) reports that it has entered into an arm’s length marketing agreements with the following [...]
La plateforme de recrutement de patients TrialWire, qui permet de redémarrer des essais cliniques interrompus, est finaliste pour de nombreux prix aux Citeline Awards 2024
13/05/2024
BOSTON, 13 mai 2024 (GLOBE NEWSWIRE) -- La plateforme de recrutement rapide de patients TrialWire™ , la seule solution de paiement à l’inscription à frais fixes fonctionnant grâce à l’IA et aux algorithmes, a été [...]
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
13/05/2024
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) , a clinical-stage biotechnology company developing a differentiated approach to treat and cure [...]
Guardion Health Sciences Announces
13/05/2024
-- Financial Results for the Three Months Ended March 31, 2024 -- Institutional Shareholder Services Issues Report Recommending that Institutional Stockholders Vote in Favor of All Proposals at the Upcoming Special [...]
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
13/05/2024
Company hosting in-person R&D day event, focused on atrioventricular interval modulation (“AVIM”) therapy, including the unmet need in hypertension, mechanism of action, clinical results and design of the BACKBEAT [...]

Pages